ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced the appointment of Kathleen M. Metters, PhD, as an independent director on March 18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced the appointment of Kathleen M. Metters, PhD, as an independent director on March 18, 2021. Dr. Metters brings over 30 years of expertise in developing therapies for chronic and autoimmune diseases. She previously served as CEO of Lycera Corp and held leadership roles at Merck & Co. Additionally, Damien Lim has transitioned off the board after 10 years. Chairman Andrew Howden expressed confidence in Dr. Metters’ ability to enhance ASLAN's clinical programs and its strategic pivot to the US market.
Positive
- Appointment of Kathleen M. Metters, PhD, brings extensive experience in immunology and drug development.
- Her expertise may positively impact ASLAN's clinical programs and strategic direction in the US.
- Management change is expected to strengthen the board's capabilities.
Negative
- Transition of Damien Lim from the board may raise concerns about continuity in leadership.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was +4.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.
Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company’s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Dr Metters holds a BSc in Biochemistry from the University of Manchester Institute for Science and Technology, and a PhD from Imperial College of Science and Technology in London.
Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years.
Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, “We are pleased to welcome Dr Metters to ASLAN’s board of directors and look forward to working with her. Kathleen is an accomplished industry leader who brings extensive scientific acumen and global development expertise in immunology. Her insight and experience, combined with that of Dr Neil Graham who recently joined the board, will provide valuable guidance to the management team as ASLAN advances its clinical programs and its pivot to the US. On behalf of the board, I would like to extend our appreciation to Damien Lim for his significant contributions to the growth of the company over the past decade.”
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6751 2021 Email: ASLAN@spurwingcomms.com | Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.